The plain takeaway: pain dropped by more than half on average, and four out of five patients cleared the bar for a meaningful improvement at one year.

Why target blood vessels in the first place?

Osteoarthritis goes deeper than bone-on-bone contact. Inflammation, abnormal blood vessel growth inside the synovium — the membrane lining the joint — and oversensitive pain nerves all feed chronic discomfort. The World Health Organization estimates knee osteoarthritis affects more than 365 million adults worldwide.

GAE aims at that vascular component. By choking off the abnormal vessels, doctors can dial down inflammation and disrupt the nerve growth that drives pain. The particles vanish within hours, leaving normal circulation intact.

"GAE is a whole new treatment regimen that targets abnormal hypervascularity around the joint and, in turn, modulates the pathological neurovascular environment," Fleckenstein said. "By reducing both inflammation and pain, GAE with resorbable microspheres may be the first procedure that alters the course of the disease, slowing its progression."

Whether the technique actually slows cartilage deterioration is unclear. The study did not measure cartilage loss or track how many patients eventually needed joint replacement.

How does this fit with prior work?

The new paper is the largest on dissolving gelatin particles. It joins a growing but uneven evidence base:

• A 2026 study in Clinical Radiology randomized 50 patients to GAE plus standard care or standard care alone. After one year, pain scores dropped 72.7% in the embolization group versus 24.2% in controls.
• A randomized, sham-controlled trial in European Radiology in April 2026 followed 58 patients. Both treatment and sham arms improved similarly, with no statistically significant difference.
• A September 2026 systematic review in the European Journal of Radiology pooled 22 studies covering 633 patients. Pain improved in most, yet no significant edge over sham emerged when three randomized trials were combined.
• A June 2026 review of 45 studies and 2,205 patients described real-world gains yet judged the evidence low or very low certainty.

The pattern: observational data look strong; controlled data look weaker. Fleckenstein's study has no sham or untreated comparison arm.

The plain takeaway: the new results are real and large, but without a sham arm they cannot separate the procedure's effect from placebo.

Could this approach replace knee surgery?

Not yet. The Society of Interventional Radiology endorsed GAE in a 2026 position statement for appropriately selected patients who cannot undergo or want to delay joint replacement, while calling for careful patient selection and continued trials.

For the many patients stuck between failed injections and unwanted surgery, the approach is real progress. "This lets us speak about safety and efficacy with real confidence," Fleckenstein said. "For the right patient, it can mean lasting relief from a single, minimally invasive procedure — a meaningful new option between injections and joint replacement."

The plain takeaway: GAE is becoming a credible bridge between conservative care and the operating room, though longer controlled trials will decide its final place.